Larazotide

Drug Profile

Larazotide

Alternative Names: AT-1001 - Alba Therapeutics; INN-202; Larazotide acetate; SPD 550

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator University of Maryland School of Medicine
  • Developer Alba Therapeutics; Alba Therapeutics Corporation; Teva Pharmaceutical Industries
  • Class Oligopeptides
  • Mechanism of Action Cell membrane permeability inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Coeliac disease; Ulcerative colitis

Highest Development Phases

  • Phase II Coeliac disease
  • Phase I Crohn's disease; Irritable bowel syndrome
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 06 Jun 2017 Innovate pharmaceuticals completes End-of-Phase II meeting with the US FDA
  • 23 Jan 2017 Chemical structure information added
  • 04 Jan 2017 Larazotide is available for licensing in (excluding USA) as of 04 Jan 2017. www.innovatebiopharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top